Could a bone marrow drug help Alzheimer's patients?
NCT ID NCT04902703
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether sargramostim, a drug already approved to stimulate bone marrow, is safe and effective for people with mild-to-moderate Alzheimer's disease. Over 6 months, 42 participants will receive either the drug or a placebo. The study will monitor side effects and measure changes in cognitive function using standard tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sargramostim (also known as Leukine or GM-CSF)
What this could lead to
If it works, this could point toward a new treatment that slows cognitive decline in Alzheimer's disease.
What could go wrong
This is a small, early-phase trial with only 42 participants, so results may not apply to everyone. The drug is being repurposed, and its effects on Alzheimer's are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••